ZZZhenyu Zhou

Zhenyu Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhenyu Zhou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Yu

    Comprehensive Ward, Nanchong Central Hospital, The Second Clinical School of North Sichuan Medical College, Nanchong, China

    1 shared publication
  • Dongying Zhang

    Department of Cardiovascular Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Guo-Qiang Cai

    Department of Cardiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Peng-Yu Zhong

    Department of Cardiology, The Second Clinical Medical College of North Sichuan Medical College, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital, 637000 Nanchong, Sichuan, China

    1 shared publication
  • Qingyi Yang

    Department of Cardiology, The Second Clinical Medical College of North Sichuan Medical College

    1 shared publication
  • Shiyong Wu

    Department of Vascular Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China

    1 shared publication

Latest Publications

  • Open Access

    Remote ischemic preconditioning reduces contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials

    by Qingyi Yang, Yi Guan, Yanling Zhang, Zhenyu Zhou

    Background: Contrast-induced nephropathy (CIN) is a common complication following coronary angiography (CA) or percutaneous coronary intervention (PCI) and is associated with prolonged hospitalization and adverse clinical outcomes. Remote ischemic preconditioning (RIPC), a noninvasive and nonpharmacological intervention, has been proposed as a potential strategy for preventing CIN. However, evidence from randomized controlled trials (RCTs) remains inconsistent. Methods: This meta-analysis of RCTs aimed to evaluate the efficacy of RIPC for preventing CIN in patients undergoing CA or PCI. The primary outcome was the incidence of CIN. For dichotomous outcomes, risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using the Mantel–Haenszel fixed-effect model. For continuous outcomes, standardized mean differences (SMDs) with 95% CIs were pooled using a fixed-effect model when heterogeneity was low and a random-effects model when substantial heterogeneity was present. Trial sequential analysis was performed for dichotomous outcomes to estimate the robustness of the cumulative evidence and the required information size. This study was prospectively registered with PROSPERO (CRD420251269657). Results: Twenty-six RCTs including 4,169 participants were included. Overall, RIPC significantly reduced the risk of CIN compared with the control treatment (RR 0.49, 95% CI 0.41–0.59, P < 0.00001; I 2 = 0%). Regarding renal function, RIPC significantly attenuated postprocedural increases in serum creatinine levels (SMD −1.00, 95% CI −1.60 to −0.39, P = 0.001) and was associated with lower postprocedural serum creatinine levels (SMD −0.23, 95% CI −0.39 to −0.08, P = 0.003). RIPC was also associated with a lower risk of major adverse events (MAEs) (RR 0.55, 95% CI 0.41–0.75, P = 0.0001). No significant differences were observed in postprocedural eGFR, neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, all-cause mortality, dialysis requirement, or rehospitalization. Conclusion: In patients undergoing coronary angiography or percutaneous coronary intervention, RIPC was associated with reduced risks of CIN and MAEs, attenuated postprocedural increases in serum creatinine levels, and lower postprocedural serum creatinine levels, while evidence for postprocedural eGFR, NGAL, cystatin C, and clinical outcomes remains inconclusive. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251269657 , PROSPERO CRD420251269657.

  • Open Access

    Catheter Ablation vs. Medical Therapy for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

    by Su-Ping Wang, Yuan Yuan, Peng-Yu Zhong, Zhen-Yu Zhou

    Background: Managing ischemic cardiomyopathy-related ventricular tachycardia (VT) remains clinically challenging since no definitive consensus exists regarding the optimal therapeutic approach. Therefore, this study aimed to assess the safety and efficacy of catheter ablation for VT in patients with ischemic cardiomyopathy. Methods: We systematically searched the PubMed, EMBASE, and Cochrane Library databases to identify pertinent clinical trials. We selected the relative risk (RR) and mean difference (MD) as the effect measures, which were calculated using Review Manager software. Additionally, we used trial sequential analysis to assess each outcome. Results: Our study included six randomized controlled trials with 1064 patients. Catheter ablation was found to reduce the risk of the composite endpoint (RR 0.83, 95% confidence interval (CI) 0.74–0.94; p = 0.002), cardiac hospitalizations (RR 0.82, 95% CI 0.71–0.95; p = 0.007), and adverse events (RR 0.75, 95% CI 0.62–0.91; p = 0.003). Additionally, no significant differences were observed between the two groups regarding VT recurrence (RR 0.94, 95% CI 0.83–1.06; p = 0.33), appropriate implantable cardioverter-defibrillator (ICD) shocks (RR 0.85, 95% CI 0.72–1.01; p = 0.06), or all-cause mortality (RR 0.93, 95% CI 0.73–1.18; p = 0.53). Conclusions: Catheter ablation reduced the incidence of composite endpoints, cardiac hospitalizations, and adverse events related to VT in patients with ischemic cardiomyopathy. However, no statistically significant differences were found between the two groups for VT recurrence, appropriate ICD shocks, and all-cause mortality. The PROSPERO Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251011744.

  • Open Access

    Corrigendum to “MicroRNA‐30‐5p Suppresses Inflammatory Factor‐Induced Endothelial Cell Injury by Targeting TCF21”

    by Zhenyu Zhou, Yu Chen, Dongying Zhang, Shiyong Wu, Tao Liu, Guoqiang Cai, Shu Qin

    [This corrects the article DOI: 10.1155/2019/1342190.].